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Abstract
Background: The BMI1 oncogene is overexpressed in several human malignancies including gastric cancer. In
addition to BMI1, mammalian cells also express Mel-18, which is closely related to BMI1. We have reported that
Mel-18 functions as a potential tumor suppressor by repressing the expression of BMI1 and consequent
downregulation of activated AKT in breast cancer cells. However, the mechanisms of BMI1 overexpression and the
role of Mel-18 in other cancers are still not clear. The purpose of this study is to investigate the role of BMI1 and
Mel-18 in gastric cancer.
Results: BMI1 was found to be overexpressed in gastric cancer cell lines and gastric tumors. Overexpression of
BMI1 correlated with advanced clinical stage and lymph node metastasis; while the expression of Mel-18 negatively
correlated with BMI1. BMI1 but not Mel-18 was found to be an independent prognostic factor. Downregulation of
BMI1 by Mel-18 overexpression or knockdown of BMI1 expression in gastric cancer cell lines led to upregulation of
p16 (p16INK4a or CDKN2A) in p16 positive cell lines and reduction of phospho-AKT in both p16-positive and p16-
negative cell lines. Downregulation of BMI1 was also accompanied by decreased transformed phenotype and
migration in both p16- positive and p16-negative gastric cancer cell lines.
Conclusions: In the context of gastric cancer, BMI1 acts as an oncogene and Mel-18 functions as a tumor
suppressor via downregulation of BMI1. Mel-18 and BMI1 may regulate tumorigenesis, cell migration and cancer
metastasis via both p16- and AKT-dependent growth regulatory pathways.
Background
Polycomb group (PcG) proteins are evolutionary con-
served gene silencers, which play an important role in
the development of vertebrate organisms. These proteins
regulate cell proliferation, senescence and tumorigenesis
via well-known growth regulatory pathways [1]. Overex-
pression of key PcG proteins such as BMI1 has been
found in several human malignancies including breast
cancer, colorectal cancer, nasopharyngeal carcinoma,
melanoma, gastric cancer, and bladder cancer [2-7].
Overexpression of BMI1 often correlates with poorer
prognosis [4,6,7]. BMI1 also plays an important role in
self-renewal of hematopoietic stem cells (HSCs), neural
stem cells and mammary stem cells [8-10].
After a finite number of cell divisions, most normal
human cells undergo cellular senescence, which consti-
tutes a powerful barrier to oncogenesis[11]. Overexpres-
sion of BMI1 has been shown to bypass this barrier in
human mammary epithelial cells and fibroblasts [12,13].
In addition to BMI1, mammalian cells also express a
BMI1-related PcG protein Mel-18 (also known as poly-
comb group ring finger 2 (PCGF2)). The Mel-18 gene
product is structurally highly similar to BMI1 protein.
Interestingly, we have found that BMI1 is negatively
regulated by Mel-18 and that Mel-18 is overexpressed
in senescent fibroblasts. Accordingly, Mel-18 overex-
pression leads to accelerated or premature senescence in
proliferating fibroblasts by repression of BMI1 [14].
Similar to human fibroblasts, expression of Mel-18
negatively correlates with BMI1 in a number of breast
cancer cell lines and breast tumors [15]. Negative corre-
lation between BMI1 and Mel-18 expression was also
recently reported in hematopoietic stem cells [16].
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cancer cell line MCF7 results in downregulation of
BMI1 and reduction of transformed phenotype. Further-
more, downregulation of BMI1 by Mel-18 overexpres-
sion and knockdown of BMI1 expression by RNA
interference (RNAi) approach is accompanied by down-
regulation of AKT/PKB (Protein Kinase B) activity [15].
Thus our data suggested that Mel-18 acts as a tumor
suppressor in breast epithelial cells. Consistent with our
data, Lee et al. also recently reported that Mel-18 nega-
tively regulates AKT and that its overexpression inhibits
growth of breast cancer cells [17]. However, the func-
tion of Mel-18 is still debatable. It is described as a
potential tumor suppressor in some studies [17-19];
while in other studies, it was found that similar to
BMI1, Mel-18 can act as an oncogene [20,21]. The
opposite role of BMI1 and Mel-18 in human fibroblasts
and breast cancer cells is an interesting finding. How-
ever, it needs to be verified in other cell types and
pathological conditions. Importantly, the role of Mel-18
in cancers other than breast and prostate cancers is still
not clear. Regulation of AKT/PKB pathway by BMI1
and Mel-18 activity also needs further confirmation.
Gastric cancer is one of the most common malignan-
cies throughout the world, and mechanisms that under-
lie the carcinogenesis of gastric cancer are still poorly
understood. It has been reported that BMI1 is overex-
pressed in gastric cancer cells and is an independent
prognosis factor [6]. However, the exact role of BMI1 in
gastric cancer is far from clear. Potential tumor suppres-
sive role of Mel-18 in gastric cancer is also not known.
Here, we show that BMI1 is overexpressed in gastric
cancer cell lines and gastric tumors, and its expression
correlated with advanced clinical stage, lymph node
metastasis, and poor prognosis. Importantly, we show
that expression of Mel-18 is decreased in gastric cancer
and is negatively correlated with the expression of BMI1
in both gastric cancer cells and normal gastric epithelial
cells. We also report that downregulation of BMI1 by
Mel-18 overexpression and knockdown of BMI1 expres-
sion in gastric cell lines is accompanied by downregula-
tion of AKT/PKB activity and upregulation of p16,
which resulted in induction of a senescence-like pheno-
type and reduction of transformed properties in gastric
cancer cell lines. These data suggest that BMI1 acts as
an oncogene via regulation of p16 and AKT/PKB, and
Mel-18 acts as a tumor suppressor via downregulation
of BMI1 during the development of gastric cancer.
Methods
Cellular and molecular reagents, and methods
An immortalized human gastric mucosal epithelial cell
line (GES-1) and eight human gastric cancer cell lines
(MKN28, MKN45, KATOIII, NCI-N87, SUN-1, SUN-
16, SGC-7901 and AGS) were obtained from the Surgi-
cal Institution of Ruijin Hospital. These cell lines were
cultured in RPMI-1640 supplemented with 10% fetal
bovine serum (FBS) and antibiotics. Stable cell lines
expressing Mel-18 or other genes of interest were gener-
ated by infection of the retroviral vectors expressing the
particular genes as described [22]. Retroviral vectors
overexpressing Mel-18, BMI1 shRNA (BMI1 i) and a
control shRNA (Ctrl i) are described earlier [14]. The
retroviruses were produced by transient transfection of
the retroviral vector together with pIK packaging plas-
mid into 293 packaging cell line as described [22].
Induction of senescence in cancer cells was determined
using Senescence-associated beta galactosidase (SA-b-
gal) assay as described [12], and the apoptosis was
determined using Annexin -FITC Apoptosis Detection
Kit (BD Biosciences, USA) as described [23]. Soft-agar
assay, wound healing assay and transwell chamber
(Corning Costar, Cambridge, MA) migration assays
were done as described [24].
Clinical samples
Seventy five paraffin-embedded gastric cancer tissue
samples and twenty two normal gastric mucosal tissue
samples were obtained from the archives of the Depart-
ment of Pathology for further immunohistochemical
analysis of different proteins expression. The clinico-
pathologic variables and survival data were obtained
from the medical records and the disease stages of the
patients were classified according to the 2002 UICC gas-
tric cancer TNM staging system. Prior patients’ consent
and approval from the Institute Research Ethics Com-
mittee were obtained for the use of clinical materials
described in the present study.
Quantitative real time RT-PCR (QRT-PCR) assays
The QRT-PCR was carried out as described [14] using
Brilliant SYBR Green QRT-PCR Master Mix, 2-Step kit
(Stratagene, La Jolla, CA). The PCR amplification was
carried out using PTC-200 Real Time PCR system (MJ
Research Inc, USA). The primers for QRT-PCR were-
GAPDH forward (F)-5’ GCTGAACGGGAAGCTCACTG
3’, GAPDH reverse (R) - 5’GTGCTCAGTGTAGCC-
CAGGA3’; BMI1 F5 ’ GCTTCAAGATGGCCGCTTG 3’,
BMI1 R5 ’ TTCTCGTTGTTCGATGCATTTC 3’;a n d
Mel-18 F5 ’ GATGGATGTGCC CAGCAAGT 3’, Mel-
18 R5 ’ GGAGCCTTGT CGCTGACTGA 3’.T h eC t
(threshold cycle) value of Mel-18 or BMI1 amplification
was normalized to that of GAPDH control. The mRNA
levels of target genes in gastric cancer cell lines were
compared with that in the immortalized human normal
gastric epithelial cell line GES-1, and when the expres-
sion showed a 2-fold increase or decrease, it was consid-
ered as an altered expression.
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Immunohistochemical analyses
BMI1 was detected using F6 mouse monoclonal anti-
b o d y( m A b )f r o mU p s t a t eC e l lS i g n a l i n gS o l u t i o n s
(Charlottesville, Virginia). Mel-18 was detected by a rab-
bit polyclonal H-115 (Santa Cruz Biotech., CA). The
9E10 mAb (Santa Cruz Biotech., CA) against c-Myc was
used to detect the expression of c-Myc tag in exogen-
ously expressed protein Mel-18. Antibodies against
human total AKT (tAKT) and phospho-AKT (ser-473,
pAKT) were obtained from Cell Signaling Technology
(Beverly, MA). Western blot analysis to detect the
altered expression of BMI1, Mel-18, and other proteins
in gastric cells were performed as described [22]. Immu-
nohistochemical (IHC) analysis to detect the expression
of Mel-18, BMI1, pAKT, and p16 in paraffin sections
was performed as described [4]. All slides were inter-
preted by two independent observers in a blinded fash-
ion. When more than 10% of the cells in a sample were
stained with moderate to strong staining, the sample
was considered positive. Otherwise, the samples were
considered negative.
Statistical analysis
All statistical analyses were done by using the SPSS 15.0
software package. Two-tailed P value less than 0.05 was
considered statistically significant. In the set of IHC
assay of paraffin-embedded tissue samples, the Pearson
c
2 test was used to determine the correlation between
t h ee x p r e s s i o no fM e l - 1 8o rB M I 1a n do t h e rp r o t e i n s ,
and clinicopathologic characteristics. Cumulative survi-
val curves were plotted by the Kaplan-Meier method
and the relationship between each of the variables and
survival was assessed by Log-rank test in a univariate
analysis. The parameters were then tested by multivari-
ate Cox proportional hazards model, which was per-
formed to identify independent variables for predicting
survival. In in vitro experiments, data were described as
mean ± SD, and analyzed by Student’s t-test.
Results
Expression of BMI1 and Mel-18 inversely correlates in
gastric cancer cell lines and gastric tumors
Our previous data showed an inverse correlation
between BMI1 and Mel-18 expression in cultured
human fibroblasts and breast cancer cells. Based on
these data, we hypothesized that gastric cancer cell lines
and gastric tumors may also express high BMI1 and low
Mel-18. To probe this hypothesis, first we analyzed the
expression of BMI1 and Mel-18 in several gastric cancer
cell lines. Our results showed that compared to GES-1,
a normal immortal human gastric mucosal epithelial cell
line, the majority of gastric cancer cell lines expressed
high BMI1 (5 out of 8 at the RNA and protein levels)
a n dl o wM e l - 1 8( 4o u to f8a tt h eR N Al e v e la n d5o u t
of 8 at the protein level) (Fig 1A, 1B).
Next, we studied the expression of Mel-18 and BMI1
in gastric tumors by IHC. IHC analysis of paraffin-
embedded archival gastric tumor samples showed that
51 of 75 (83.6%) samples exhibited positive staining for
BMI1 while only one sample out of 21 normal gastric
mucosal tissue samples (1/21, 4.8%) was scored positive
for BMI1. Furthermore, 15 of 75 (24.5%) of the gastric
tumor samples and 12 of 21 (57.1%) of the normal gas-
tric mucosal tissue samples showed a positive staining
for Mel-18. Compared with normal gastric mucosal tis-
sues, gastric tumor tissues expressed significantly higher
BMI1 and lower Mel-18 (Table 1). The correlation ana-
lysis between BMI1 and Mel-18 proteins expression also
showed a strong negative correlation in the gastric
tumors and normal gastric mucosal tissues (P = 0.002,
Table 1, Fig 1C).
Overexpression of BMI1 correlates with high
phosphorylated AKT and low p16
We have previously reported that p16 and AKT are
potential cancer-relevant targets of BMI1 and Mel-18 in
human fibroblasts and breast cancer cells respectively.
To determine whether BMI1 and Mel-18 regulate p16
and AKT during gastric carcinogenesis, we analyzed the
expression of p16 and phosphorylated AKT in gastric
cancer cell lines and gastric cancer tissues. We found
that the normal immortal human gastric mucosal
epithelial cell line GES-1 expressed high levels of p16;
while 3 of 8 gastric cancer cell lines expressed lower
levels of p16, and 5 of 8 gastric cancer cell lines did not
express any detectable p16. Importantly, cell lines with
low or no p16 overexpressed BMI1 suggesting a nega-
tive correlation between t h ee x p r e s s i o no fB M I 1a n d
p16 (Fig 1B). Compared to GES-1, all of the gastric can-
cer cell lines expressed high level of phosphorylated
AKT. Thus the overexpression of BMI1 correlated with
high AKT activity and low p16 in gastric cancer cell
lines (Fig 1B).
Next, we carried out IHC analysis of archival paraffin-
embedded gastric tumor biopsies. The results showed
that 43 of 75 (57.3%) tumor biopsies and 15 of 21
(71.4%) normal gastric mucosal tissue samples stained
positively for p16. On the other hand, 56.0% (42 of 75)
of gastric cancer tissues and 14.3% (3 of 21) of normal
gastric mucosal tissues stained positively for phospho-
AKT. Statistical analysis of data showed that compared
to normal gastric mucosal tissues, gastric tumors
expressed significantly high phosphorylated AKT and
low levels (but not significant) of p16 (Table 1). The
correlation between Mel-18 and p16 or phosphorylated
AKT was also not significant. However, correlation ana-
lysis showed that the overexpression of BMI1 negatively
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Page 3 of 12Figure 1 Mel-18 and BMI1 expression inversely correlates in gastric cancer cell lines and gastric tumors. A) Mel-18 (left) and BMI1 (right)
expression in an immortalized human normal gastric epithelial cell line GES-1 and various gastric cancer cell lines as detected by QRT-PCR
analysis. The bars indicate mean ± SD from three different experiments. B) BMI1, Mel-18, phospho-AKT (pAKT), total AKT (tAKT), and p16 proteins
expression in an immortalized human normal gastric epithelial cell line GES-1 and various gastric cancer cell lines as detected by Western blot
analysis. b-actin was used as a loading control. C) A representative figure of two gastric tumor samples. Sample 1 expresses high Mel-18, low
BMI1, low pAKT, and high p16, while the second sample expresses low Mel-18, high BMI1, high pAKT, and low p16. Tissue sections were stained
with BMI1, Mel-18-, pAKT-, or p16- specific antibodies and counterstained with hematoxylin as described in experimental procedures.
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Page 4 of 12correlated with low level of p16, and positively corre-
lated with high phospho-AKT (Table 1, Fig 1C).
The correlation between the expression of BMI1 and Mel-
18 with clinicopathologic characteristics and prognosis
There was a significant positive correlation between
BMI1 expression with lymph node metastasis, or clinical
stage in paraffin-embedded archival gastric tumor sam-
ples as the expression of BMI1 was significantly higher
in the patients with positive lymph node metastasis, or
late stage disease (Table 2). Overexpression of phospho-
AKT also positively correlated with depth of invasion
(T classification), or lymph node metastasis (N classifi-
cation), and the expression of p16 negatively correlated
with lymph node metastasis (Table 2). Multivariate Cox
proportional hazards model analysis, which included
gender, age, tumor size, histology, T classification,
lymph node metastasis, distant metastasis, clinical stage,
and the expression of Mel-18, BMI1, phospho-AKT and
p16 proteins, showed that BMI1 protein expression, and
clinical stage were independent prognostic indicators of
overall survival, while Mel-18 was not the independent
prognostic indicator. The 5-year survival rate in the
BMI1 positive group was significantly lower than that in
the BMI1 negative group (23.3% vs. 50.0%, p < 0.001.
Fig 2). These results suggest that overexpression of
BMI1 correlates with the poor prognosis of patients
with gastric cancer.
Overexpression of Mel-18 results in down-regulation of
BMI1 and induction of senescence in gastric cancer cells
As the expression of Mel-18 and BMI1 inversely corre-
lated in gastric cancer cell lines and gastric tumors, we
suspected that similar to breast cancer cells, Mel-18
may negatively regulate the expression of BMI1 in gas-
tric cancer cells. To probe this hypothesis, we transiently
transfected SGC-7901 cells with a Mel-18 overexpres-
sing plasmid and measured the changes in the expres-
sion of BMI1. We found that overexpression of Mel-18
resulted in down-regulation of BMI1 expression in
SGC-7901 cells (Fig 3C). To determine if downregula-
tion of BMI1 by Mel-18 overexpression resulted in
induction of a senescence-like phenotype, we performed
SA-b-gal staining. The results showed that overexpres-
sion of Mel-18 indeed induced senescence in SGC-7901
gastric cancer cells (Fig 3A and 3B). Stable cell lines
which overexpress Mel-18 also showed a decreased
expression of BMI1 in SGC-7901 (Fig 4C), AGC, and
NCI-N87 gastric cell lines (data not shown). To deter-
mine whether BMI1 can also inversely regulate Mel-18
expression, we stably expressed BMI1 shRNA in SGC-
7901 cells, and examined expression of Mel-18. Our
results showed an efficient knockdown of BMI1 but no
change in expression of Mel-18 suggesting that BMI1
does not regulate Mel-18 expression (Fig. 4D).
Overexpression of Mel-18, as well as knockdown of BMI1
results in reduction of transformed phenotype in gastric
cancer cells
We determined the transformation potential of control
and Mel-18 overexpressing SGC-7901 cells using ancho-
rage-independence growth assay, and determined the
induction of senescence and apoptosis by SA-b-gal
staining and Annexin V staining respectively. The
results indicated that Mel-18 overexpression in SGC-
7901 cells which express detectable p16 led to an
increase in senescence and a decrease in colony forma-
t i o ni ns o f ta g a r( F i g .4 A ) .C o m p a r e dt oc o n t r o l ,t h e
Table 1 The expression of Mel-18, BMI1, pAkt, and p16; and the correlations between these proteins in gastric cancer
tissues and normal gastric mucosa tissues.
Mel-18 n (%) BMI1 n (%) pAkt n (%) p16 n (%)
(-) (+) P value (-) (+) P value (-) (+) P value (-) (+) P value
Tissues
Normal mucosa 9(42.9) 12(57.1) 20(95.2) 1(4.8) 18(85.7) 3(14.3) 6(28.6) 15(71.4)
Gastric cancer 59(78.7) 16(21.3) 0.001* 32(42.7) 43(57.3) <.0001* 33(44.0) 42(56.0) 0.0007* 32(42.7) 43(57.3) 0.243
Proteins
Bmi-1
Negative (-) 29(56.9) 22(43.1)
Positive (+) 38(86.4) 6(13.7) 0.002*
pAkt
Negative (-) 36(72.0) 14(28.0) 35(70.0) 15(30.0)
Positive (+) 32(69.6) 14(30.4) 0.793 17(37.0) 29(63.0) 0.0012*
p16
Negative (-) 31(81.6) 7(18.4) 11(28.9) 27(71.1) 18(47.4) 20(52.6)
Positive (+) 37(63.8) 21(36.2) 0.061 41(70.7) 17(29.3) <.0001* 33(56.9) 25(43.1) 0.360
*Data were analyzed by the c2-test and p < 0.05 was considered to be significant
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Page 5 of 12Table 2 Correlations between the expression of BMI1, Mel-18, pAkt, p16 proteins and clinicopathologic variables
Variables Mel-18 n (%) BMI1 n (%) pAkt n (%) p16 n (%)
(-) (+) P value (-) (+) P value (-) (+) P value (-) (+) P value
Gender
Male 40(80) 10(20) 21(42) 29(58) 21(42) 29(58) 20(40) 30(60)
Female 19(76) 6(24) 0.6902 11(44) 14(56) 0.8689 12(48) 13(52) 0.6217 12(48) 13(52) 0.509
Age (years)
<60 27(84.4) 5(15.6) 14(43.8) 18(56.2) 17(53.1) 15(46.9) 15(46.9) 17(53.1)
≥60 32(74.4) 11(25.6) 0.2979 18(41.9) 25(58.1) 0.87 16(37.2) 27(62.8) 0.1696 17(39.5) 26(60.5) 0.525
Size(cm)
<4.5 34(81.0) 8(19.0) 18(42.9) 24(57.1) 20(47.6) 22(52.4) 18(42.9) 24(57.1)
≥4.5 25(75.8) 8(24.2) 0.5857 14(42.4) 19(57.6) 0.97 13(39.4) 20(60.6) 0.4763 14(42.4) 19(57.6) 0.6177
Histology
Well
differentiated
23(74.2) 8(25.8) 14(45.2) 17(54.8) 13(41.9) 18(58.1) 12(38.7) 19(61.3)
Poorly
differentiated
36(81.8) 8(18.2) 0.4274 18(40.9) 26(59.1) 0.7139 20(45.5) 24(54.5) 0.7139 20(45.5) 24(54.5) 0.5609
T classification
T1/2 21(84) 4(16) 13(52) 12(48) 15(60) 10(40) 9(36) 16(64)
T3/4 38(76) 12(24) 0.4253 19(38) 31(62) 0.2478 18(36) 32(72) 0.0484* 23(46) 27(54) 0.4091
LNM
Negative 33(80.5) 8(19.5) 25(61.0) 16(39.0) 24(58.5) 17(41.5) 13(31.7) 28(68.3)
Positive 26(76.5) 8(23.5) 0.6725 7(20.6) 27(79.4) 0.0004* 9(26.5) 25(73.5) 0.0054* 19(55.9) 15(44.1) 0.0351*
Distant metastasis
Negative 55(80.9) 13(19.1) 31(45.6) 37(54.4) 32(47.1) 36(52.9) 29(42.6) 39(57.4)
Positive 4(57.1) 3(42.9) 0.1443 1(14.3) 6(85.7) 0.1108 1(14.3) 6(85.7) 0.0963 3(42.9) 4(57.1) 0.9915
Clinical stage
I/II 25(86.2) 4(13.8) 18(62.1) 11(37.9) 16(57.1) 12(42.9) 11(39.3) 17(60.7)
III/IV 34(73.9) 12(26.1) 0.2056 14(30.4) 32(69.6) 0.007* 17(36.2) 30(63.8) 0.0768 21(44.7) 26(55.3) 0.6477
Abbreviations: LNM, lymph node metastases. *Data were analyzed by the c2-test and p < 0.05was considered to be significant.
Figure 2 BMI1 is an independent prognostic marker in gastric cancer patients. A) Kaplan-Meyer survival curves were plotted as cumulative
survival vs months according to BMI1 expression (negative and positive). B) Kaplan-Meier survival curves were plotted according to clinical stage
(stage I/II and stage III/IV).
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overexpressing SGC-7901 cells (Fig. 4A upper panel),
and the soft agar colonies in Mel-18 overexpressing
SGC-7901 cells were less in frequency and also smaller
in size (Fig. 4A middle panel). We also determined the
senescence and anchorage-independent growth potential
of SGC-7901 cells, which stably express BMI1 shRNA.
Western blot analysis of BMI1 indicated efficient knock-
down of BMI1 expression in these cells (Fig. 4D).
Furthermore, stable expression of BMI1 shRNA in SGC-
7901 cells led to a significant increase of number of
senescent cells and decrease in number of colonies in
soft-agar indicating a decrease in transformed phenotype
of these cells (Fig. 4B). Annexin V staining suggested no
difference in apoptosis between Mel-18 overexpressing
cells, BMI1 knock-down cells and control cells (Fig 4A
and 4B lower panels), indicating that in gastric cancer
cells BMI1 downregulation does not cause significant
cell death. We also found that overexpression of Mel-
18, as well as knockdown of BMI1 expression induces
Figure 3 Transient transfection of Mel-18 in SGC-7901 cells results in the downregulation of BMI1 and increased senescence in a
dose-dependent manner. A) Transient transfection of Mel-18 results in increased senescence in a dose-dependent manner as determined by
SA-b-gal staining analysis. SGC-791 cells were transfected with 0, 1.5, and 3 μg of Mel-18 overexpressing plasmid and analyzed for the induction
of senescence using SA-b-gal assay. B) Senescent cells (SA-b-gal positive) from three different experiments were counted and plotted. C)
Transient transfection of Mel-18 in SGC-7901 cells results in the dose-dependent downregulation of BMI1 as determined by Western blot
analysis, b-actin serves as internal control ( upper panel: Mel-18, BMI1, and b-actin were detected by Western blot; lower panel: quantification of
the levels of Mel-18 and BMI1. The levels of Mel-18 and BMI1 were quantified by densitometric analysis of signal present in each lane using
ImageJ 1.37v software (NIH, Bethesda, USA) and normalized to b-actin signal of each lane, and plotted. ).
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another gastric cancer cell line which expresses p16, and
in NCI-N87 cells which do not express detectable p16
(data not shown). These results showed that overexpres-
sion of Mel-18, or knockdown of BMI1 reduces malig-
nancy of both p16 positive and p16-negative gastric
cancer cell lines, suggesting that the mechanism of
reduction in malignancy by BMI1 downregulation is at
least in part independent of p16 pathway.
Overexpression of Mel-18, as well as knockdown of BMI1
expression inhibits cell migration in gastric cancer cells
Because expression of Mel-18 or BMI1 correlated with
lymph node metastasis, we hypothesized that these PcG
proteins may regulate cancer metastasis. In support of
this hypothesis, we used an in vitro cell migration model
to measure the effect of Mel-18 and BMI1 on cell
migration, which is one of the important steps in cancer
metastasis. First, we analyzed the migration distance of
Figure 4 Reduction of transformed phenotype by Mel-18 overexpression and knockdown of BMI1 expression. A) Overexpression of Mel-
18 in SGC-7901 cells results in increased cellular senescence (p < 0.05; upper panel: left, pictures of SA-b-gal stained cells; right, senescent cells
were counted and plotted), decreased number of colonies in soft agar (p < 0.01, mid panel: left, pictures of colonies in soft agar, right, the
number of colony were counted and plotted); and no difference in apoptosis (lower panel). The bars indicate mean ± SD. Vector infected cells
served as a control. B) Knockdown of BMI1 in SGC-7901 results in increased cellular senescence (p < 0.05; upper panel: left, pictures of SA-b-gal
stained cells, right, senescent cells were counted and plotted); decreased number of colonies in soft agar (p < 0.05; mid panel: left, pictures of
colonies in soft agar, right, the number of colony were counted and plotted); and no difference in apoptosis (lower panel). Ctrli (non-specific
sequence) served as control for BMI1 knockdown (BMI1i). C) Overexpression of Mel-18 leads to downregulation of BMI1, and reduction in pAKT
(phospho-AKT) and upregulation of p16 expression as determined by Western blot analysis ( left, Mel-18, BMI1, pAKT, tAKT (total AKT), p16, and
b-actin were detected by Western blot; right, quantification of the levels of BMI1 and p16, and AKT activity by densitometric analysis as
described in Figure 3 ). D) BMI1 knockdown by RNAi approach leads to no change of Mel-18, reduction in pAKT and upregualtion of p16
expression as determined by Western blot analysis (left, pictures of Western blot; right, quantification of the levels of Mel-18 and p16, and AKT
activity by densitometric analysis).
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wound healing assay. The results showed that the
migration distance of Mel-18 overexpressed SGC-7901
cells, as well as BMI1 knockdown SGC-7901 cells, was
decreased significantly compared to the control cells
(Fig 5A). Next, we measured the migration potential of
cells by Transwell chambers. Results using Transwell
chambers also showed that the number of migrated cells
decreased significantly in Mel-18 overexpressed SGC-
7901 cells, as well as in BMI1 knockdown SGC-7901
cells, compared to that of control cells (Fig 5B). We also
determined the effect of Mel-18 overexpression and
BMI1 knockdown on migration in NCI-N87 cells which
do not express detectable p16. Our data suggested that
similar to SGC-7901 cells, BMI1 downregulation in
NCI-N87 cells lead to decrease in migration (data not
shown). In summary, our results suggest that Mel-18
and BMI1 may regulate cell migration and that BMI1
overexpression may contribute to metastasis. Our data
also suggest that regulation of migration by BMI1 and
Mel-18 may be independent of p16.
Mel-18 and BMI1 regulate p16 expression and AKT
activity in gastric cancer cell lines
To determine the possible mechanisms of decreased
transformed phenotype, and migration inhibition in
gastric cancer cell lines by Mel-18 overexpression or
knockdown of BMI1 expression, we examined the
expression of p16 and phosphorylated AKT in control
and Mel-18 overexpressing or BMI1 knockdown cells.
Consistent with our previous data that BMI1 and Mel-
18 may regulate p16 and AKT, results showed that
BMI1 downregulation by Mel-18 overexpression or
RNAi approach leads to upregulation of p16 and
substantial reduction in phospho-AKT in SGC-7901
cells suggesting that BMI1 regulates AKT activity
(Fig. 4C, 4D). In NCI-N87 cells which do not express
detectable p16, we also found that overexpression of
Mel-18 or knockdown of BMI1 inhibits AKT activity
(data not shown).
Discussion
Arguably BMI1 is the most well studied PcG protein
that is known to regulate proliferation and senescence
in mammalian cells. It not only inhibits senescence and
immortalizes human mammary epithelial cells (HMECs)
[13], but it can also transform keratinocytes via downre-
gulation of tumor suppressors and differentiation related
factors[25]. It also cooperates with H-Ras to transform
HMECs via dysregulation of multiple growth-regulatory
pathways [24], and plays a central role in mediating leu-
kemic transformation and development [26]. Aberrant
Figure 5 Mel-18 overexpression as well as BMI1 knockdown in SGC-7901 cells inhibits cell migration. A) W o u n dh e a l i n ga s s a y sw e r e
performed by plating cells in 6-well culture dishes. Cells were scratched in the middle and then further incubated for 8 hrs and 15 hrs, and the
wound widths were examined under a light microscope. The migration distance of Mel-18 overexpressed SGC-7901 cells (upper panel), as well
as BMI1 knockdown cells (lower panel), was decreased compared with that of control cells. Vector and Ctrl i serve as control for Mel-18
overexpression, and BMI1 knockdown (BMI1i) respectively. B) Transwell migration assays using the Corning chamber showed that fewer number
of cells migrated in SGC-7901 cells with Mel-18 overexpression or BMI1 knockdown compared with that in control (p < 0.05; left, picture of
migrated cells; right, the number of migrated cells were counted and plotted).
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cancers and its overexpression is often correlated with
poor prognosis in many types of cancers[2-7]. Most
importantly, BMI1 is required for self-renewal of normal
and malignant stem cells [8-10]. Hence, BMI1 is consid-
ered an important therapy target [27,28]. Because BMI1
is an important regulator of cell proliferation and stem
cell phenotype, its own regulators are likely to be very
important for onocogenesis and self-renewal of normal
and cancer stem cells.
We have previously reported that BMI1 is regulated
by another PcG protein Mel-18 in human fibroblasts
[14], and that by doing so Mel-18 can potentially func-
tion as a tumor suppressor. Potential tumor suppressor
role of Mel-18 has also been suggested in few other stu-
dies [15,17]. In the present study we provide in vitro
and in vivo evidences supporting this notion during gas-
tric cancer development. Overexpression of BMI1 in
gastric cancer has been previously reported [6,29], how-
ever the potential mechanism of its overexpression
remained unclear. Here we confirmed previous observa-
tion that BMI1 is overexpressed in gastric cancer cell
lines and gastric tumors and that BMI1 overexpression
correlates with poor prognosis.
Importantly, here we show that Mel-18 is downregu-
lated in gastric cancer cells and gastric tumors, and that
there is a negative correlation between Mel-18 and
BMI1 expression in gastric cancer cells. Thus, our data
suggest that overexpression of BMI1 in gastric tumors
and cell lines may due to downregulation of Mel-18 in
gastric cancer cells. Consistent with its tumor suppres-
sor role, we also found that Mel-18 negatively regulated
AKT expression, and induced p16 expression and senes-
cence in gastric cancer cell lines. In a recent study,
BMI1 overexpression was closely related with the Lau-
ren’sa n dB o r r m a n n ’s classification and clinical stage in
gastric tumors [29]. However, in our study we did not
find correlation between BMI1 expression and tumor
size, T classification or differentiation in gastric tumors,
w h i c hw a sn o tc o n s i s t e n tw i t ht h ein vitro study that
BMI1 regulates proliferation. The discrepancy could be
due to the limited number of samples in our study or
other interfering factors. However, we did find that
BMI1 overexpression positively correlated with lymph
node metastasis, and clinical stages of the tumors. Our
in vitro study also showed that overexpression of Mel-
18, and knockdown of BMI1 expression, inhibit the abil-
ity of migration in gastric cancer cells. It’s the first time
to find that Mel-18 and Bmi-1 regulate cellular migra-
tion in in vitro model, and provide preliminary direct
evidence for the possibility of Mel-18 and Bmi-1 regu-
late the metastasis of cancer. Collectively, our data sug-
gest that Mel-18 and BMI1 not only play important
roles in tumorigenesis, but may also involve in the pro-
gression and metastasis of gastric cancer.
It is interesting to note that our data suggest that
BMI1 but not the Mel-18 is an independent negative
prognosis factor. Patients with high BMI1 expression
survived significantly shorter than those with low or no
BMI1 expression suggesting that BMI1 is a key regulator
and a valuable molecular marker of therapy failure in
gastric cancer patients. It also suggest that BMI1 may be
regulated by factors other than Mel-18, and that Mel-18
could only partially regulate BMI1, particularly during
advanced stages of gastric cancer, which can explain
why Mel-18 expression correlated with BMI1 but was
not an independent prognosis factor.
Taken together, gastric tumor tissues expressed signif-
icantly higher BMI1 and lower Mel-18 compared with
normal gastric mucosal tissues, and BMI1 correlated
with lymph node metastasis, clinical stages, and prog-
nosis. Hence, detection of Mel-18 and BMI1 expression
may be helpful in supporting the diagnosis and deter-
mining the prognosis of gastric cancer in clinical
practice.
Although INK4A/ARF locus is the most cancer rele-
vant target of BMI1 and Mel-18, there are several new
reports, which suggest that these PcG proteins, in parti-
cular BMI1 may regulate tumorigenesis independent of
p16 pathway [17,24,25,30]. Our present data using gas-
tric cancer cells also suggest that BMI1 and Mel-18 can
regulate tumorigenesis, cell migration and metastasis at
least partially independent of p16, which is a known
tumor suppressor involved in regulation of cell prolifera-
tion and possibly metastasis [31-33]. Another important
target of BMI1 and Mel-18 appears to be AKT [15],
which is known to regulate tumorigenesis and cancer
metastasis in several cancers [34-36]. Accordingly, our
present study suggests that regulation of gastric tumori-
genesis and metastasis by Mel-18 and BMI1 may involve
AKT, which was overexpressed in gastric cancer tissues
and positively correlated with the depth of invasion and
lymph node metastasis in gastric cancer patients.
Conclusions
In summary, our studies suggest that Mel-18 and BMI1
play important but opposite roles in the tumorigenesis,
progression and metastasis during gastric cancer devel-
opment; BMI1 acts as an oncogene, while Mel-18 func-
tions as a tumor suppressor. Additionally, Mel-18 and
BMI1 may regulate tumorigenesis, cell migration and
cancer metastasis via both p16- and AKT-dependent
pathways. Finally our studies suggest that determination
of the expression of BMI1 and Mel-18 may help in sup-
porting the diagnosis and determining the prognosis of
gastric cancer in clinical practice.
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